News Releases Year None2024202320222021 May 7, 2024 YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer April 29, 2024 YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule April 19, 2024 YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 April 18, 2024 YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine April 16, 2024 YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 April 9, 2024 YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine April 3, 2024 YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility March 5, 2024 YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries February 22, 2024 YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 February 16, 2024 YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting Pagination Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds Contact IR
Year None2024202320222021 May 7, 2024 YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer April 29, 2024 YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule April 19, 2024 YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 April 18, 2024 YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine April 16, 2024 YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 April 9, 2024 YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine April 3, 2024 YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility March 5, 2024 YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries February 22, 2024 YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 February 16, 2024 YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting Pagination Current page 1 Page 2 Next page next › Last page last »